Background: Pulmonary TB and DM are a combination of high medical-epidemiological conflict and high global impact because they are interdependent. Pulmonary TB cannot improve in the presence of unmanaged diabetes. Pulmonary TB in people with DM has particular characteristics, so if it is not diagnosed and treated, it is difficult to understand the effects of TB drugs and oral antidiabetic drugs. The purpose of this study was to compare the length of treatment for drug-resistant pulmonary TB in the presence vs. the absence of type 2 DM Methods: This study used a cross-sectional with a single population proportion method. The research subjects were enrolled using the consecutive sampling technique. The comparison was between drug-resistant TB patients with and without type 2 DM. The total sample was initially recruited was 80 patients, and after applying the inclusion and exclusion criteria, 22 study subjects remained. Results: The 80 samples studied were 44 drug-resistant pulmonary TB patients with type 2 DM and 36 patients without type 2 DM. The male:female ratio was 53 (66.3%) to 27 (33.8%). GeneXpert results in both groups indicated rifampicin resistance. In the comparison of length of treatment, drug-resistant pulmonary TB patients with type 2 DM who stayed on their treatment until recovery most often recovered in the 18th to 24th months, totalling 13 people, whereas the drug-resistant pulmonary TB patients without type 2 DM who stayed on their treatment until recovery recovered in the 6th to 24th months, totalling 9 people (Mann‒Whitney test P = 0.000). Conclusions:The treatment period for drug-resistant pulmonary tuberculosis patients with type 2 DM is much longer than that for drug-resistant pulmonary tuberculosis patients without type 2 DM.

Background The impact of the coronavirus disease 2019 (COVID-19) pandemic on tuberculosis (TB) was great enough for COVID-19 to replace TB as the leading cause of death worldwide. The WHO Global Tuberculosis Report 2020 stated that the number of TB cases reported was 845,000. The pandemic caused a decline in the detection of tuberculosis cases, and the attention of the Indonesian government became more focused on making COVID-19 a top priority in prevention and control measures so that tuberculosis cases were neglected. Methods This study used a cross-sectional. The research subjects were recruited using the consecutive sampling technique. The variable of this study was a comparison between pulmonary TB with confirmed COVID-19 and pulmonary TB without COVID-19 using the research subjects for total sampling. Bivariate analysis was used, which was carried out on two compared variables. Results Based on the results of this study, of the 127 samples studied, 101 pulmonary TB patients without COVID-19 and 26 pulmonary TB patients with confirmed COVID-19 were declared cured. This was observed more often among male patients than among female patients. Among TB patients with confirmed COVID-19, two age groups dominated, namely, the 17–25 (23.1%) and > 64 (23.1%) age groups. Moreover, most TB patients without COVID-19 were in the 26–35 age group (23.8%). The results of the length of treatment analysis among pulmonary TB patients without COVID-19 showed ≥ 6 months (82.2%) until these patients were cured. Moreover, the length of treatment for pulmonary TB patients with confirmed COVID-19 until they were declared cured was 7–9 months (61.5%). In this study, the number of pulmonary tuberculosis patients without COVID-19 who had type 2 DM (Diabetes Mellitus) was 77.1%. Conclusions The treatment period for pulmonary tuberculosis patients with confirmed COVID-19 was significantly longer than that for pulmonary tuberculosis patients without COVID-19.